DEF: TerrAscend Corp. to Hold Annual Shareholder Meeting on June 24, 2025; Proposes Option Amendments

TerrAscend Corp. will hold its annual shareholder meeting virtually on June 24, 2025, to discuss financial results, elect directors, ratify the auditor, and vote on amendments to insider stock options.

Summary

• TerrAscend Corp. will hold its annual meeting of shareholders virtually on June 24, 2025, at 1:00 p.m. Eastern Time.
• Shareholders will consider the audited consolidated financial statements for the year ended December 31, 2024.
• The meeting will include the election of five director nominees.
• Shareholders will vote to ratify the re-appointment of MNP LLP as the auditor for the fiscal year ending December 31, 2025.
• A key proposal involves approving amendments to 3,706,250 stock options held by certain insiders, modifying their exercise prices.
• The record date for determining shareholders entitled to vote is April 25, 2025.
• Shareholders can attend the meeting virtually or be represented by proxy.
• The corporation is using notice-and-access to provide meeting materials online, but paper copies are available upon request.
• Jason Wild, the Executive Chairman, controls 31.05% of the Common Shares as of the record date.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily presenting factual information about the upcoming shareholder meeting and proposals. The sentiment is slightly positive due to the company's efforts to align executive compensation with shareholder interests.

Positives

• The company is providing meeting materials online, reducing costs and environmental impact.
• Shareholders have the option to attend the meeting virtually or vote by proxy, increasing accessibility.
• The proposed option amendments are intended to better align the interests of Subject Insiders with those of the Shareholders more generally.
• The Board recommends that Shareholders vote FOR the Option Amendment Resolution.

Negatives

• The proposed option amendments may be perceived negatively by some shareholders as benefiting insiders.
• The broader cannabis capital markets have been susceptible to market volatility and steep decline.

Risks

• Cannabis remains illegal under U.S. federal law, posing a significant risk to the business.
• Enforcement of federal laws in the United States is a significant risk to the business of the Corporation and any proceedings brought against the Corporation thereunder may adversely affect its operations and financial performance.
• The broader cannabis capital markets have been susceptible to market volatility and steep decline.

Future Outlook

The document outlines the business to be conducted at the annual meeting, including the election of directors and the approval of executive compensation plans, but does not provide a specific future outlook for the company's performance.

Management Comments

• The Board has determined that adverse changes in the market price of the Common Shares since the below-listed Options were granted could materially interfere with the Corporations efforts and ability to retain the services of the Subject Insiders.
• The Board has further determined that it is in the best interests of the Corporation to approve the Insider Option Amendments (as defined below) to be more in line with the market price of the Common Shares and with a view to motivating the achievement of the Corporations long-term strategic objectives and thereby better aligning the interests of Subject Insiders with those of the Shareholders more generally.

Industry Context

The document highlights the legal restrictions and regulations governing the cannabis industry in the United States, noting that cannabis remains a Schedule I drug under federal law. This context is crucial for understanding the risks and challenges faced by TerrAscend, which operates in this sector.

Comparison to Industry Standards

• The document does not provide a direct comparison to industry standards.
• However, it mentions that the Compensation Committee reviews public disclosures of comparable cannabis companies to ensure executive compensation is competitive.
• The document mentions Heron Therapeutics, Inc. and Veloxis Pharmaceuticals, Inc. as companies where some of TerrAscend's directors and officers have held positions.

Related Party Transactions

• During the year ended December 31, 2024, certain funds controlled by Jason Wild, a related party of the Corporation, invested $5,500,000, as a member of a loan syndicate, of the FG Loan, as described in the section titled 'Interest of Informed Persons in Material Transactions.'

Stakeholder Impact

• Shareholders are directly impacted by the proposals being voted on, including the election of directors and the approval of executive compensation.
• Employees and executives are impacted by the proposed changes to stock option plans.
• The company's overall performance and governance impact its stakeholders, including customers, suppliers, and creditors.

Next Steps

• Shareholders need to review the proxy materials and vote on the proposals by the specified deadline.
• The company will hold the annual meeting on June 24, 2025, to discuss and vote on the outlined matters.

Key Dates

Keywords

TerrAscend, shareholder meeting, proxy statement, stock options, directors, auditor, cannabis, governance, MNP LLP, Jason Wild